TrialAnticancer research2011

Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Matthew G Fury et al.PubMed ↗Full text ↗

No numbers read from the abstract.